Hepatitis B virus (HBV) infection remains an urgent global health concern, affecting hundreds of millions of people and significantly heightening the risk of severe liver complications, including ...

With NIH funding, the group will pursue research and patient care approaches for a disease that affects more than 250 million people around the globe ...

The introduction of highly effective direct-acting antivirals has transformed the HCV treatment landscape, enabling cure ...

The Johns Hopkins Medicine-led, multinational Hepatitis B and HIV Cure Consortium, colloquially known as the BICC, was recently established through ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Hepatitis B is one of the most widespread viral infections in the world, with hundreds of millions of people living with it today. Caused by the hepatitis B virus (HBV), this condition primarily ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Transmission electron micrograph showing hepatitis B virus particles (colored orange). The Johns Hopkins Medicine-led ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

Nearly 300 students showed off their scientific skills during the recent 74th annual Reading-Berks Science and Engineering Fair. The event, the second-oldest science fair in the country, was held ...

Earlier antiviral treatment in children with chronic hepatitis B is linked to faster viral clearance and improved long-term liver outcomes.